Immutep (ASX:IMM, IMMP) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism.
Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the late 1990s that a soluble protein called LAG-3 could activate dendritic cells in the vicinity of tumour cells. Dendritic cells are antigen presenting cells (APCs) which stimulate T-cells to trigger an immune response to cancer. The activation of T-cells is key to long-run remission in cancer.
Immutep was previously known as Prima BioMed, with